All Landscape Reports

Next-Gen Research Tools: Breaking the Preclinical Data Paradox

April 12, 2026

This report profiles 79 companies across 8 categories building better preclinical research tools, from organs-on-chips to digital twins, that are breaking the paradox between founders who need data and investors who need conviction.

The Antibody-Drug Conjugate Landscape

April 6, 2026

HOUSTON tracks 229 companies across the ADC ecosystem — 187 therapeutic developers, 18 platform companies, and 15 CDMOs/services. In just four months, the space generated $2.73B+ in licensing deals.

Early-Stage AI In Biotech

April 6, 2026

The most comprehensive mapping of early-stage AI in biotech — 569 companies spanning drug discovery, diagnostics, digital health, and the tools infrastructure powering all of it. Featuring $8B+ in deal value tracked since December 2025.

RNA-Based Therapeutics

April 5, 2026

This report catalogs 252 early-stage companies developing RNA-based therapeutics or enabling RNA drug discovery and delivery across seven distinct modalities.

The Future of AI Drug Discovery

April 5, 2026

221 early-stage companies using AI/ML to discover and design therapeutics — powered by HOUSTON intelligence.

Next-Gen Research Tools: Breaking the Preclinical Data Paradox

April 12, 2026

This report profiles 79 companies across 8 categories building better preclinical research tools, from organs-on-chips to digital twins, that are breaking the paradox between founders who need data and investors who need conviction.

The Future of AI Drug Discovery

April 5, 2026

221 early-stage companies using AI/ML to discover and design therapeutics — powered by HOUSTON intelligence.

The Antibody-Drug Conjugate Landscape

April 6, 2026

HOUSTON tracks 229 companies across the ADC ecosystem — 187 therapeutic developers, 18 platform companies, and 15 CDMOs/services. In just four months, the space generated $2.73B+ in licensing deals.

Early-Stage AI In Biotech

April 6, 2026

The most comprehensive mapping of early-stage AI in biotech — 569 companies spanning drug discovery, diagnostics, digital health, and the tools infrastructure powering all of it. Featuring $8B+ in deal value tracked since December 2025.

RNA-Based Therapeutics

April 5, 2026

This report catalogs 252 early-stage companies developing RNA-based therapeutics or enabling RNA drug discovery and delivery across seven distinct modalities.